drugset / Trial / NCT00688012

Safety Study of SPC3649 in Healthy Men

NCT00688012

Phase 1 Completed 64 enrolled Santaris Pharma A/S
RandomizedQuadruple-blindTreatment

Summary

A placebo-controlled, double-blind, randomized, single dose, dose escalating trial in healthy men to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SPC3649.

Timeline

Start
2008-05
Primary completion
2009-05
Completion
2009-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Miravirsen Antisense oligonucleotide